Last reviewed · How we verify
NCT06687590: POINT FORCE
Serranator POINT FORCE Registry
trial testing Peripheral balloon angioplasty in Peripheral Artery Disease (PAD) in 500 participants. Currently enrolling.
31 August 2026
Quick facts
| Lead sponsor | Cagent Vascular LLC |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 22 January 2025 |
| Primary completion | 31 August 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Peripheral balloon angioplasty
Conditions studied
- Peripheral Artery Disease (PAD) — all drugs for Peripheral Artery Disease (PAD) →
- Dysfunctional AV Fistula — all drugs for Dysfunctional AV Fistula →
- Dysfunctional AV Graft — all drugs for Dysfunctional AV Graft →
Sponsor
Cagent Vascular LLC — full company profile →
Who can join
18 and older, any sex, with Peripheral Artery Disease (PAD) or Dysfunctional AV Fistula. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this registry is to collect observational data under local standard of care and evaluate safety and performance of the Serranator® in treatment of peripheral artery disease (PAD), or dysfunctional native or synthetic arteriovenous dialysis fistulae in a real-world scenario. The data and conclusions derived from this study will be used to provide clinical evidence for the clinical evaluation process.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06687590
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral Artery Disease (PAD)
Currently open trials in the same condition.
- NCT07226193 — Detecting Peripheral Artery Disease With the Pulse · NA · recruiting
- NCT07313410 — Using Near-Infrared Light to Better Understand Peripheral Artery Disease · recruiting
- NCT07169045 — Validity and Reliability of the 6-minute Stepper Test in Patients With Peripheral Artery Disease · recruiting
- NCT06605209 — Safety and Effectiveness of the Peripheral Balloon-Expandable Covered Stent System for Iliac Artery Stenosis/Occlusion. · NA · recruiting
- NCT06621264 — Exercise Activity to Improve Mobility in Patients With CKD and PAD · NA · recruiting
Other Cagent Vascular LLC trials
Trials by the same sponsor.
- NCT06434194 — Serrantor OCT Study · NA · recruiting
- NCT03693963 — The PRELUDE BTK Study · NA · completed
- NCT03001700 — PRospective Study for the TrEatment of Atherosclerotic Lesions in the Superficial Femoral and/or Popliteal Arteries Usin · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06687590 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cagent Vascular LLC
- Last refreshed: 13 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06687590.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing